Elosulfase alfa

BNF:

not assigned

Status:

Red

Decision Date:

July 2014

Comments

RED:^1,2,3 NICE HST2 - For the treatment of mucopolysaccharidosis type IV (Morquio A syndrome) (Decision date - January 2016)

RED 1,2,3: NICE HST19 - for treating mucopolysaccharidosis type 4A. (Decision date - May 2022)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again